Regulation of ABCB1 Activity by MicroRNA-200c and MicroRNA-203a in Breast Cancer Cells: the Quest for MicroRNAs' Involvement in Cancer Drug Resistance

Overview

Journal Cancer Drug Resist

Date 2022 May 18

PMID 35582584

Authors

Ana Armada

Bruno Costa Gomes

Miguel Viveiros

Jose Rueff

Antonio Sebastiao Rodrigues

Affiliations

Soon will be listed here.

Abstract

ABCB1 is a major player in cancer drug resistance. The purpose of this study was to functionally assess the regulation of ABCB1 activity in a doxorubicin-resistant breast cancer cell line by miR-200c and miR-203. Human breast carcinoma cell lines MCF-7 (Doxorubicin-sensitive and not expressing ABCB1) and KCR (Doxorubicin-resistant and expressing ABCB1) were used to evaluate the expression levels of miR-200c and miR-203 by Real-time quantitative PCR (RT-qPCR). The effects of transient ectopic expression of miRNA-200c and miR-203 on the expression of ABCB1 in KCR and MCF-7 cells was verified by RT-qPCR and Western Blot. The extrusion activity of the ABCB1 pump was analyzed by fluorescence microscopy and flow cytometry through fluorescence substrate retention assays (DiOC) in the presence and absence of the ABCB1 inhibitor verapamil. RT-qPCR results indicated a 100,000-fold increase in ABCB1 mRNA expression levels in KCR cells compared to MCF-7 cells, and is inversely correlated with the expression of miR-203 and miR-200c. The insertion of miR-200c and miR-203 led to a higher retention of DiOC within KCR cells, and slightly reduced the protein levels of ABCB1 in KCR cells, although the high initial expression of ABCB1 masked the reduction in protein levels. The increased intracellular accumulation of the fluorescent due DiOC in the presence of the ABCB1 inhibitor verapamil correlated with the inhibition caused by miR-203 and miR-200c in transfected cells. The present study demonstrates that miR-200c and miR-203 exert a negative modulating effect on the activity of ABCB1 associated with doxorubicin resistance.

Citing Articles

MiRNAs function in the development of resistance against doxorubicin in cancer cells: targeting ABC transporters.

Lu X, Jin H Front Pharmacol. 2024; 15:1486783.

PMID: 39679367 PMC: 11638538. DOI: 10.3389/fphar.2024.1486783.

MicroRNA-203a inhibits breast cancer progression through the PI3K/Akt and Wnt pathways.

Entezari M, Soltani B, Sadeghizadeh M Sci Rep. 2024; 14(1):4715.

PMID: 38413784 PMC: 10899204. DOI: 10.1038/s41598-024-52940-5.

microRNAs in cancer chemoresistance: The sword and the shield.

Mondal P, Meeran S Noncoding RNA Res. 2022; 6(4):200-210.

PMID: 34977437 PMC: 8669341. DOI: 10.1016/j.ncrna.2021.12.001.

ABC Efflux Transporters and the Circuitry of miRNAs: Kinetics of Expression in Cancer Drug Resistance.

Gomes B, Honrado M, Armada A, Viveiros M, Rueff J, Rodrigues A Int J Mol Sci. 2020; 21(8).

PMID: 32340269 PMC: 7215654. DOI: 10.3390/ijms21082985.

References

Armada A, Martins C, Spengler G, Molnar J, Amaral L, Rodrigues A . Fluorimetric Methods for Analysis of Permeability, Drug Transport Kinetics, and Inhibition of the ABCB1 Membrane Transporter. Methods Mol Biol. 2016; 1395:87-103. DOI: 10.1007/978-1-4939-3347-1_7. View

Liu Y, Gao S, Chen X, Liu M, Mao C, Fang X . Overexpression of miR-203 sensitizes paclitaxel (Taxol)-resistant colorectal cancer cells through targeting the salt-inducible kinase 2 (SIK2). Tumour Biol. 2016; 37(9):12231-12239. DOI: 10.1007/s13277-016-5066-2. View

Tomono T, Yano K, Ogihara T . Snail-Induced Epithelial-to-Mesenchymal Transition Enhances P-gp-Mediated Multidrug Resistance in HCC827 Cells. J Pharm Sci. 2017; 106(9):2642-2649. DOI: 10.1016/j.xphs.2017.03.011. View

Seiden M, Swenerton K, Matulonis U, Campos S, Rose P, Batist G . A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol. 2002; 86(3):302-10. DOI: 10.1006/gyno.2002.6762. View

Zhou Y, Wan G, Spizzo R, Ivan C, Mathur R, Hu X . miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. Mol Oncol. 2013; 8(1):83-92. PMC: 4124530. DOI: 10.1016/j.molonc.2013.09.004. View

Katayama K, Kapoor K, Ohnuma S, Patel A, Swaim W, Ambudkar I . Revealing the fate of cell surface human P-glycoprotein (ABCB1): The lysosomal degradation pathway. Biochim Biophys Acta. 2015; 1853(10 Pt A):2361-70. PMC: 4558211. DOI: 10.1016/j.bbamcr.2015.06.001. View

Singh A, Settleman J . EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29(34):4741-51. PMC: 3176718. DOI: 10.1038/onc.2010.215. View

Li T, Gao F, Zhang X . miR-203 enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer. Oncol Rep. 2014; 33(2):607-14. DOI: 10.3892/or.2014.3646. View

Chen J, Tian W, Cai H, He H, Deng Y . Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol. 2011; 29(4):2527-34. DOI: 10.1007/s12032-011-0117-4. View

10.

Haenisch S, Werk A, Cascorbi I . MicroRNAs and their relevance to ABC transporters. Br J Clin Pharmacol. 2014; 77(4):587-96. PMC: 3971975. DOI: 10.1111/bcp.12251. View

11.

Chung F, Santiago J, Jesus M, Trinidad C, See M . Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter?. Am J Cancer Res. 2016; 6(8):1583-98. PMC: 5004065. View

12.

Obayashi M, Yoshida M, Tsunematsu T, Ogawa I, Sasahira T, Kuniyasu H . microRNA-203 suppresses invasion and epithelial-mesenchymal transition induction via targeting NUAK1 in head and neck cancer. Oncotarget. 2016; 7(7):8223-39. PMC: 4884988. DOI: 10.18632/oncotarget.6972. View

13.

Armada A, Gazarini M, Goncalves L, Antunes S, Custodio A, Rodrigues A . Generation of an antibody that recognizes Plasmodium chabaudi cysteine protease (chabaupain-1) in both sexual and asexual parasite life cycle and evaluation of chabaupain-1 vaccine potential. Exp Parasitol. 2013; 135(1):166-74. DOI: 10.1016/j.exppara.2013.06.009. View

14.

Hamano R, Miyata H, Yamasaki M, Kurokawa Y, Hara J, Moon J . Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res. 2011; 17(9):3029-38. DOI: 10.1158/1078-0432.CCR-10-2532. View

15.

Lebedeva I, Pande P, Patton W . Sensitive and specific fluorescent probes for functional analysis of the three major types of mammalian ABC transporters. PLoS One. 2011; 6(7):e22429. PMC: 3142157. DOI: 10.1371/journal.pone.0022429. View

16.

Crowley E, McDevitt C, Callaghan R . Generating inhibitors of P-glycoprotein: where to, now?. Methods Mol Biol. 2009; 596:405-32. PMC: 7121335. DOI: 10.1007/978-1-60761-416-6_18. View

17.

Sui H, Cai G, Pan S, Deng W, Wang Y, Chen Z . miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer. Mol Cancer Ther. 2014; 13(12):3137-51. DOI: 10.1158/1535-7163.MCT-14-0167. View

18.

Liang X, Chen C, Zhao Y, Wang P . Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol. 2009; 596:467-88. PMC: 3047496. DOI: 10.1007/978-1-60761-416-6_21. View

19.

Gromicho M, Dinis J, Magalhaes M, Fernandes A, Tavares P, Laires A . Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1. Leuk Lymphoma. 2011; 52(10):1980-90. DOI: 10.3109/10428194.2011.584005. View

20.

Kopp F, Oak P, Wagner E, Roidl A . miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression. PLoS One. 2012; 7(11):e50469. PMC: 3510180. DOI: 10.1371/journal.pone.0050469. View